Table 1 Effect of various ITS in mice with human lymphoma xenografts
Specificity | Tumor Cells | Mice | Tumor Type | IT | Treatment | Therapeutic Effect | Reference |
|---|---|---|---|---|---|---|---|
Anti-CD22 | CA46 | Nude | Solid | RFB4-PE35 | Earlya | Prevents tumor growth | (25) |
| Â | Ramos | Nude | Solid | CLB-B-ly/1-rRTA | Lateb | Temporary reduction of tumor growth | (20) |
| Â | Ramos | SCID | Disseminated | CLB-B-ly/1-rRTA | Late | Tumor-free animals at 175 days | (20) |
|  | Daudi | SCID | Disseminated | RFB4-RTdgA | Early | MPT (31 → 67 days) | (28) |
|  |  |  |  |  | Late | MPT (26 → 54 days) | (28) |
|  | Daudi | SCID | Disseminated | RFB4-RTdgA + HD37-RTdgA | Early | MPT (30 → 103 days) | (29) |
| Â | Daudi | SCID | Disseminated | RFB4-RTdgA + HD37-RTdgA + | Early | Tumor-free animals at 150 days | (30) |
| Â | Â | Â | Â | Doxorubicin | Â | Â | Â |
|  |  |  |  |  | Late | MPT (30 → 120 days) | (31) |
Anti-CD 19 | Namalwa | SCID | Disseminated | B4-bRT | Early | ST50 from 9 → 46 days | (32) |
|  | (i.p.) | SCID | Disseminated | B4 | Early | ST50 from 9 → 36 days | (32) |
|  | Nalm-6 | SCID | Disseminated | B4-bRT | Late | ST50 from 25 → 30 days | (32) |
|  | Namalwa | SCID | Disseminated | B4-bRt | Late | ST50 from 27 → 41 days | (32) |
| Â | Â | Â | Â | B4 | Late | No effect | (32) |
|  | Namalwa | SCID | Disseminated | B4-bRT | Late | MST from 23 → 33 days | (33) |
|  |  |  |  | B4-bRT + Doxorubicin | Late | MST from 23 → 48 days | (33) |
|  | Daudi | SCID | Disseminated | HD37-RTdgA | Early | MPT from 30 → 55 | (29) |
|  |  |  |  | HD37-RTdgA + RFB4 [F(ab’)2] | Early | Tumor-free animals at 1 year | (27) |
|  | Nalm-6-UM1 | SCID | Disseminated | B43-PAP | Early | 38% mice, MST from 38 → 74 days | (34) |
|  |  |  |  | (high dose) |  | 62% mice, MST from 38 → 210 days | (34) |
|  |  |  |  | B43-PAP + Cyclophosphamide | Early | 90% mice, MST from 38 → 74 days | (35) |
| Â | Nalm-6 | SCID | Disseminated | BU12-SAP | Late | 40% tumor-free animals at 110 days | (36) |